Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be ...

FLT3-ITD MRD dynamics predicted relapse risk and shaped response to gilteritinib maintenance in post-transplant AML.

The DFS and MRD event-free rate was 66 percent at 24 months after osimertinib. "Plasma-based, tumor-informed MRD analysis may predict disease recurrence during adjuvant treatment and during ...

Next-generation sequencing powered liquid biopsies can be an effective way to detect residual cancer after primary treatment.

A meta-analysis of 29 RCTs found significant associations between MRD negativity and better PFS and OS outcomes. Sensitive assays, such as next-generation sequencing, are crucial for detecting MRD ...

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial.

Circulating tumor DNA (ctDNA) is a powerful tool in cancer diagnostics that can be measured to assess the presence or absence of molecular residual disease (MRD) in a patient’s blood.

Data from the expanded MRD analysis of the Phase 3 CEPHEUS study show the addition of DARZALEX FASPRO ® to bortezomib, lenalidomide and dexamethasone (D-VRd) leads to improved and deepened rates ...

Roy S. Herbst, MD, PhD, from Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and colleagues examined whether tumor-informed, circulating tumor DNA-based MRD could predict ...